Global Clinical Submission Lead Executive Director– Pfizer
Dr. Belen Carrillo-Rivas has worked for Pfizer for more than seven years and currently serves as Global Clinical Submissions Lead, being the decision maker on submission readiness and accountable for the quality, accuracy and consistency of clinical data for major submissions to regulatory agencies across the Oncology, Gene Therapy, and Rare Disease portfolios. She previously held the position of Lead of Pfizer CURES. Belen designed and developed Pfizer CURES, a new arm aimed to develop an innovative clinical development approach and build novel partnerships and alliances to extend the scientific and clinical development opportunities for a select number of quality assets in Pfizer’s portfolio that have the potential to offer significant benefits to patients. Before this work, she held the position of Head R&D Innovation, Operations, and Strategy at the BioTherapeutics R&D division. Belen was responsible for the Division’s portfolio, strategy, and operations. Belen was instrumental in building Pfizer’s Biotherapeutics entrepreneurial R&D units, leading a project centered valuation driven initiative that resulted in the consolidation of the current pipeline while also supporting the advancement of more than 25 novel R&D programs spanning from discovery up to Phase 3 across multiple therapeutic areas. Belen served a cornerstone role in the formation and institution of the Pfizer Centers for Therapeutic Innovation (CTI), a pioneering R&D Unit within Pfizer that drives product development partnerships with world-leading academic medical centers, by leading the development of the business plan and communications strategy. Belen leads the identification, creation, and implementation and of key strategic and operational initiatives in direct support of R&D activities. In realizing this effort, she established the next level of precision medicine for PFE’s chronic disease R&D activities leading and executing four collaborations with 23andMe. Belen was instrumental in the realization of the Pfizer’s End-to-End Biologics initiative aimed at transforming Pfizer’s science and approach in the development of optimized biologics across all stages of the drug development process. She also led the identification and establishment of the Pfizer-MIT Synthetic Biology Alliance, leading and executing three ground-breaking deals. Finalist “50 on Fire” BostInno (Boston Innovation ) 2014 Awards for Healthcare & Medicine Innovation. Prior to her work in the pharmaceutical industry, Belen held senior leadership R&D positions at several biotech companies; Resolvyx Pharmaceuticals Inc., Peptimmune Inc., Daiichi Sankyo Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., where she led a significant efforts focused on the discovery and development of small molecule, novel lipid therapeutics and peptides for the treatment autoimmune disease (including multiple sclerosis), cardiovascular and respiratory diseases Belen was awarded with the most prestigious Spanish Government Overseas Postgraduate Studentship, and she received her Doctorate’s degree from Oxford University in Oxford, U.K. She was a Post-Doctoral Research Fellow at Harvard Medical School.